Kura Oncology, Inc. (KURA) Cash Flow Statement
Kura Oncology, Inc. (KURA) generated -$111.8M of operating cash flow over the twelve months to 2026-06-30, spent $5.7M on capital expenditure and had free cash flow of -$117.4M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
KURAKura Oncology, Inc.Follow KURA — free
—
Price chart with a free account
- Market cap
- 854.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 4 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating cash flow | 134.3 | -64.1 | -111.8 | |
| Capital expenditure | 0.5 | 6.6 | -5.7 | |
| Free cash flow | 133.8 | -70.7 | -117.4 | |
| Stock-based compensation | 33.9 | 37.1 | — |
USD millions · SEC XBRL
Kura Oncology, Inc. — questions
- What is Kura Oncology, Inc.'s operating cash flow?
- -$111.8M over the twelve months to 2026-06-30.
- How much does Kura Oncology, Inc. spend on capital expenditure?
- $5.7M over the twelve months to 2026-06-30.
- What is Kura Oncology, Inc.'s free cash flow?
- -$117.4M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Kura Oncology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.